

# Development of a First in class Immunotherapy for Treatment of Non small cell lung cancer with PD L1 negative/low



ONCOLOGY	Non-Clinical
Product Type	Immunoglobulin Product (mAb)
Indication	1) 1st :NSCLC, 2 nd : H&N cancer, Colon cancer, Cholangiocarcinoma
Target	CMG
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• CMG is expressed on various cancers</li> <li>• CMG binds to its binding partner to inhibit T cell activation</li> <li>• WM-A1 blocks the interaction of CMG and binding partner, thereby inducing T-cell mediated tumor cell death</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• WM-A1 is a novel immunotherapeutic monoclonal antibody</li> <li>• No competitive drugs for the same target, “First-in Class”</li> <li>• Predictive Biomarker</li> </ul>
Development Stage	Non-Clinical
Route of Administration	Parenteral-Intravenous